Trial Profile
Long-term treatment, multicenter, open-label study with SPP100 [aliskiren] in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- 14 Nov 2005 New trial record.